Back to results
US 9,416,360 B2Granted
Base modified oligonucleotides
AssigneeMiragen Therapeutics, Inc.
InventorsKurt Vagle, Christina Dalby, William S. Marshall
Life of this patent
Estimating the term…
Abstract
The present invention relates to oligonucleotides with base modified nucleosides for enhancement of binding affinity.
Claims16
A base modified antisense oligonucleotide, comprising:
- at least one nucleotide having both:
- a) a 2′ modification;
- and
- b) an amino carbonyl base modification at the C-5 position of a pyrimidine base,
- wherein the oligonucleotide is from about 5 to about 25 nucleotides in length and contains one or more phosphorothioate linkages;
- and
- wherein the 2′ modification is 2′-OMe and the amino carbonyl modified pyrimidine base has the following structure:
- wherein R is at least one member selected from the group consisting of:
5 more elements
Dependencies are inferred from the claim text.